VEGF-targeted therapy: therapeutic potential and recent advances.
about
Recent developments in receptor tyrosine kinases targeted anticancer therapyRapid copper acquisition by developing murine mesothelioma: decreasing bioavailable copper slows tumor growth, normalizes vessels and promotes T cell infiltrationCucurbitacin-I (JSI-124) activates the JNK/c-Jun signaling pathway independent of apoptosis and cell cycle arrest in B leukemic cells.The tumor microenvironment of colorectal cancer: stromal TLR-4 expression as a potential prognostic markerAssociations of VEGF/VEGF-receptor and HGF/c-Met promoter polymorphisms with progression/regression of retinopathy of prematurity.Bevacizumab treatment in the elderly patient with metastatic colorectal cancer.Vascular endothelial growth factor receptors: molecular mechanisms of activation and therapeutic potentials.Expression of Hypoxia-inducible factor 1-α and vascular endothelial growth factor-C in locally advanced breast cancer patients.Intracranial hemorrhage in patients treated with bevacizumab: report of two cases.Targeting signal transduction pathways in metastatic breast cancer: a comprehensive review.Clinical development of VEGF signaling pathway inhibitors in childhood solid tumors.Green tea catechins inhibit angiogenesis through suppression of STAT3 activation.Angiogenesis inhibitors and the need for anti-angiogenic therapeutics.Radionuclide carriers for targeting of cancer.Primary signet ring cell carcinoma of the appendix: a rare case report and our 18-year experienceMolecular Biomarkers of Response to Antiangiogenic Therapy for Cancer.Autocrine VEGF signaling promotes cell proliferation through a PLC-dependent pathway and modulates Apatinib treatment efficacy in gastric cancer.Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomes.Advances in novel drug delivery strategies for breast cancer therapy.Role of the antiangiogenic agent bevacizumab in the treatment of elderly patients with metastatic colorectal cancer.Metabolic surgery and cancer: protective effects of bariatric procedures.Bevacizumab: overview of the literature.Nanoparticle-mediated delivery of siRNA for effective lung cancer therapy.SR16388: a steroidal antiangiogenic agent with potent inhibitory effect on tumor growth in vivo.Immunohistochemical expression of vascular endothelial growth factor in canine oral squamous cell carcinomas.Level of endothelial cell apoptosis required for a significant decrease in microvessel density.Visualization of tumor angiogenesis using MR imaging contrast agent Gd-DTPA-anti-VEGF receptor 2 antibody conjugate in a mouse tumor model.Plasma vascular endothelial growth factor A and placental growth factor: novel biomarkers of pulmonary hypertension in congenital diaphragmatic hernia.Polymorphisms in the VEGFA and VEGFR-2 genes and neovascular age-related macular degeneration.[(99m)Tc(CO)(3)]-radiolabeled bevacizumab: in vitro and in vivo evaluation in a melanoma model.Expression of vascular endothelial growth factor and caspase-3 in mucinous breast carcinoma and infiltrating ductal carcinoma-not otherwise specified, and the correlation with disease-free survival.Immunotherapeutic Targeting of Tumor-Associated Blood Vessels.Interleukin-1 receptor antagonist inhibits angiogenesis in gastric cancer.Affinity of Indocyanine Green in the Detection of Colorectal Peritoneal Carcinomatosis.The hematopoietic cell transplantation-specific comorbidity index (HCT-CI) is an outcome predictor for partially matched related donor transplantation.Phosphorylated VEGFR2 and hypertension: potential biomarkers to indicate VEGF-dependency of advanced breast cancer in anti-angiogenic therapy.Intravital microscopy in the study of the tumor microenvironment: from bench to human application.
P2860
Q26751331-5A0AFBA6-6C86-476D-A220-DF44E4ABFFE0Q27307762-8B7EA937-A449-455A-A3A2-C63047C6F321Q33942430-02DF7A7B-C8C5-42FF-8E95-B4DF2A565FE8Q34380094-8F32B6EA-6DD9-4F60-872B-38B4AADE096EQ34456779-5DFE245D-1F67-4687-8CFC-7F925C94EB4BQ34899949-919CD3A4-312C-4299-90C3-DA87C770611FQ35049227-F48C4369-5FC3-425D-B5B7-54558AE623C3Q35179664-403CBBD5-3927-45B1-8369-5C8659852A02Q35555755-A1533A04-3B97-4CD8-B68C-E1733872261FQ35583942-806558FB-08F9-4F57-ADE7-0BDF4BAF7A0FQ35599819-69CC0683-D614-4C9B-BB44-ECFC0822E8DEQ36876370-EBF99F2A-A681-46C1-B20B-6D51F8B88B3AQ36949560-652926C2-3B9C-47E2-AAE8-0ABC6A065613Q37237705-000CFCF9-B08D-45C3-8D5B-A3FD6180BFB9Q37356475-D561751C-7E2D-43B6-A1AB-49874015140CQ37377316-C465973E-34B8-4F04-AC4B-0AEA2C02B90FQ37707033-C247CBAD-EB73-428F-9346-AF04530B813FQ37723370-2F5B34E2-AF79-46A3-990D-11A19B454654Q37777142-9297AFD7-E09B-453A-87BB-61520755F31DQ37820653-787DF0D6-05FE-46AE-9FB5-015E8074099CQ37867582-E2CADDE9-B933-41FD-B44F-6856233EB5FCQ38010797-94D2C05E-38E4-407B-BB30-F2E0B9BBECC7Q38451918-0454B199-92B8-4D51-8AA0-AAF1AF0C5B75Q39628302-C40C5DF6-2075-47B1-8F04-60E8DE2279CFQ40002486-32DDCBB3-5683-4D16-8E0B-549849E7E329Q40201066-3AEACB89-5B04-4D23-BD39-B0D38B134B31Q41510549-8DCA04A0-9562-447F-9DC8-0DF795DAFC4AQ41722390-3E3D29BC-B55C-44A7-A841-31DED2D6D3AFQ42953147-E87F2398-E991-4B02-9A5B-F8AA69201C87Q44448280-B29EAE1E-A704-45D9-AB1D-541316BE2D83Q45736517-531BA05F-C8D5-4AD7-BCC4-4962E88800E2Q49592831-FE4D942E-6D13-4D50-B41F-CD76E1936728Q49981026-46C9137D-4350-4F7A-A4B3-70E41AB3AA24Q50213736-0884F5C2-5F9C-484E-A9E1-B226CECD8323Q50863410-723F4D99-CD10-493D-A05A-2D21E6A2DFB2Q54393339-BE492C5F-11E2-4AAB-8B03-841FD6D0EF6EQ55020615-8FAB80D6-4A1A-4CFA-9A84-DD5142CB0B4B
P2860
VEGF-targeted therapy: therapeutic potential and recent advances.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
VEGF-targeted therapy: therapeutic potential and recent advances.
@ast
VEGF-targeted therapy: therapeutic potential and recent advances.
@en
type
label
VEGF-targeted therapy: therapeutic potential and recent advances.
@ast
VEGF-targeted therapy: therapeutic potential and recent advances.
@en
prefLabel
VEGF-targeted therapy: therapeutic potential and recent advances.
@ast
VEGF-targeted therapy: therapeutic potential and recent advances.
@en
P1433
P1476
VEGF-targeted therapy: therapeutic potential and recent advances.
@en
P2093
Lee S Rosen
P304
P356
10.1634/THEONCOLOGIST.10-6-382
P577
2005-06-01T00:00:00Z